Repurposing metformin for cancer treatment

Current clinical studies

Young Kwang Chae, Ayush Arya, Mary Kate Malecek, Daniel Sanghoon Shin, Benedito A Carneiro Filho, Sunandana Chandra, Jason B Kaplan, Aparna Kalyan, Jessica K Altman, Leonidas C Platanias, Francis Joseph Giles

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated decreased cancer incidence and mortality in patients taking metformin. Several clinical trials, focused on evaluation of metformin as an anti-cancer agent are presently underway. Data published from a small number of completed trials has put forth intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy. Another interesting observation was made in patients with breast cancer, wherein a trend towards improvement in cancer proliferation markers was noted in patients without insulin resistance. Data on survival outcomes with the use of metformin as an anti-cancer agent is awaited. This manuscript will critically review the role of metformin as a potential cancer treatment.

Original languageEnglish (US)
Pages (from-to)40767-40780
Number of pages14
JournalOncotarget
Volume7
Issue number26
DOIs
StatePublished - Jan 1 2016

Fingerprint

Metformin
Neoplasms
Therapeutics
Clinical Trials
Immunomodulation
Endometrial Neoplasms
Clinical Studies
Insulin Resistance
Observation
Breast Neoplasms
Survival
Mortality
Incidence

Keywords

  • Cancer
  • Clinical trials
  • Metformin

ASJC Scopus subject areas

  • Oncology

Cite this

Chae, Y. K., Arya, A., Malecek, M. K., Shin, D. S., Carneiro Filho, B. A., Chandra, S., ... Giles, F. J. (2016). Repurposing metformin for cancer treatment: Current clinical studies. Oncotarget, 7(26), 40767-40780. https://doi.org/10.18632/oncotarget.8194
Chae, Young Kwang ; Arya, Ayush ; Malecek, Mary Kate ; Shin, Daniel Sanghoon ; Carneiro Filho, Benedito A ; Chandra, Sunandana ; Kaplan, Jason B ; Kalyan, Aparna ; Altman, Jessica K ; Platanias, Leonidas C ; Giles, Francis Joseph. / Repurposing metformin for cancer treatment : Current clinical studies. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 40767-40780.
@article{7cb372a3e06a41608cd0083d92948ef7,
title = "Repurposing metformin for cancer treatment: Current clinical studies",
abstract = "In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated decreased cancer incidence and mortality in patients taking metformin. Several clinical trials, focused on evaluation of metformin as an anti-cancer agent are presently underway. Data published from a small number of completed trials has put forth intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy. Another interesting observation was made in patients with breast cancer, wherein a trend towards improvement in cancer proliferation markers was noted in patients without insulin resistance. Data on survival outcomes with the use of metformin as an anti-cancer agent is awaited. This manuscript will critically review the role of metformin as a potential cancer treatment.",
keywords = "Cancer, Clinical trials, Metformin",
author = "Chae, {Young Kwang} and Ayush Arya and Malecek, {Mary Kate} and Shin, {Daniel Sanghoon} and {Carneiro Filho}, {Benedito A} and Sunandana Chandra and Kaplan, {Jason B} and Aparna Kalyan and Altman, {Jessica K} and Platanias, {Leonidas C} and Giles, {Francis Joseph}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.8194",
language = "English (US)",
volume = "7",
pages = "40767--40780",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

Chae, YK, Arya, A, Malecek, MK, Shin, DS, Carneiro Filho, BA, Chandra, S, Kaplan, JB, Kalyan, A, Altman, JK, Platanias, LC & Giles, FJ 2016, 'Repurposing metformin for cancer treatment: Current clinical studies', Oncotarget, vol. 7, no. 26, pp. 40767-40780. https://doi.org/10.18632/oncotarget.8194

Repurposing metformin for cancer treatment : Current clinical studies. / Chae, Young Kwang; Arya, Ayush; Malecek, Mary Kate; Shin, Daniel Sanghoon; Carneiro Filho, Benedito A; Chandra, Sunandana; Kaplan, Jason B; Kalyan, Aparna; Altman, Jessica K; Platanias, Leonidas C; Giles, Francis Joseph.

In: Oncotarget, Vol. 7, No. 26, 01.01.2016, p. 40767-40780.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Repurposing metformin for cancer treatment

T2 - Current clinical studies

AU - Chae, Young Kwang

AU - Arya, Ayush

AU - Malecek, Mary Kate

AU - Shin, Daniel Sanghoon

AU - Carneiro Filho, Benedito A

AU - Chandra, Sunandana

AU - Kaplan, Jason B

AU - Kalyan, Aparna

AU - Altman, Jessica K

AU - Platanias, Leonidas C

AU - Giles, Francis Joseph

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated decreased cancer incidence and mortality in patients taking metformin. Several clinical trials, focused on evaluation of metformin as an anti-cancer agent are presently underway. Data published from a small number of completed trials has put forth intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy. Another interesting observation was made in patients with breast cancer, wherein a trend towards improvement in cancer proliferation markers was noted in patients without insulin resistance. Data on survival outcomes with the use of metformin as an anti-cancer agent is awaited. This manuscript will critically review the role of metformin as a potential cancer treatment.

AB - In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated decreased cancer incidence and mortality in patients taking metformin. Several clinical trials, focused on evaluation of metformin as an anti-cancer agent are presently underway. Data published from a small number of completed trials has put forth intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy. Another interesting observation was made in patients with breast cancer, wherein a trend towards improvement in cancer proliferation markers was noted in patients without insulin resistance. Data on survival outcomes with the use of metformin as an anti-cancer agent is awaited. This manuscript will critically review the role of metformin as a potential cancer treatment.

KW - Cancer

KW - Clinical trials

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=84982074226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982074226&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8194

DO - 10.18632/oncotarget.8194

M3 - Article

VL - 7

SP - 40767

EP - 40780

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -